Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial

Share this Article

Singapore Med J 2013; 54(7): 387-390; http://dx.doi.org/10.11622/smedj.2013139
Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial

Sarbolouki S, Javanbakht MH, Derakhshanian H, Hosseinzadeh P, Zareei M, Hashemi SB, Dorosty AR, Eshraghian MR, Djalali M
Correspondence: Dr Mahmoud Djalali, mjalali87@yahoo.com

ABSTRACT
Introduction Diabetes mellitus is the most common metabolic disorder in humans, and its incidence is increasing rapidly worldwide. Although polyunsaturated fatty acids have beneficial effects on diabetes mellitus, previous data regarding the possible positive effects of n-3 fatty acids on glycaemic indices were inconclusive. We conducted a double-blind randomised clinical trial to determine the effects of eicosapentaenoic acid (EPA), an n-3 polyunsaturated fatty acid, on overweight patients with type 2 diabetes mellitus (T2DM).
Methods This double-blind, placebo-controlled randomised clinical trial was conducted on a total of 67 overweight patients with T2DM for a duration of three months. Of these 67 patients, 32 received 2 g purified EPA daily, while 35 received a placebo of 2 g corn oil daily. The patients’ fasting plasma glucose (FPG), serum insulin, glycated haemoglobin (HbA1c) and insulin sensitivity indices were assessed.
Results After three months of EPA supplementation, the group that received EPA showed significant decreases in FPG (p < 0.001), HbA1c (p = 0.01) and homeostasis model assessment of insulin resistance (HOMA-IR) (p = 0.032), when compared to the placebo group. EPA supplementation resulted in decreased serum insulin levels, with the levels between the EPA and placebo groups showing a significant difference (p = 0.004).
Conclusion The results of our study indicate that EPA supplementation could improve insulin sensitivity. It was able to decrease serum insulin, FPG, HbA1c and HOMA-IR. EPA could have beneficial effects on glycaemic indices in patients with T2DM.

Keywords: diabetes mellitus, eicosapentaenoic acid, insulin sensitivity
Singapore Med J 2013; 54(7): 387-390; http://dx.doi.org/10.11622/smedj.2013139

REFERENCES

1. International Diabetes Federation. Diabetes Atlas. Belgium: IDF, 2000.
 
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53.
http://dx.doi.org/10.2337/diacare.27.5.1047
 
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-53.
http://dx.doi.org/10.1016/S0140-6736(98)07019-6
 
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
http://dx.doi.org/10.1136/bmj.321.7258.405
 
5. Nettleton JA, Katz R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 2005; 105:428-40.
http://dx.doi.org/10.1016/j.jada.2004.11.029
 
6. Sirtori CR, Crepaldi G, Manzato E, et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance: reduced triglyceridemia, total cholesterol and increased HDL-C without glycaemic alterations. Atherosclerosis 1998; 137:419-27.
http://dx.doi.org/10.1016/S0021-9150(97)00298-0
 
7. Borkman M, Chisholm DJ, Furler SM, et al. Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes 1989; 38:1314-9.
http://dx.doi.org/10.2337/diabetes.38.10.1314
 
8. Vessby B. n-3 fatty acids and blood glucose control in diabetes mellitus. J Intern Med Suppl 1989; 731:207-10.
 
9. Axelrod L, Camuso J, Williams E, et al. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double33 blind, controlled study. Diabetes Care 1994; 17:37-44.
http://dx.doi.org/10.2337/diacare.17.1.37
 
10. Browning LM, Krebs JD, Moore CS, et al. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 2007; 9:70-80.
http://dx.doi.org/10.1111/j.1463-1326.2006.00576.x
 
11. Navas-Carretero S, Pérez-Granados AM, Schoppen S, Vaquero MP. An oily fish diet increases insulin sensitivity compared to a red meat diet in young iron-deficient women. Br J Nutr 2009; 102:546-53.
http://dx.doi.org/10.1017/S0007114509220794
 
12. Funnell MM, Brown TL, Childs BP, et al. National standards for diabetes self management education. Diabetes Care 2012; 35 suppl 1:S101-S8.
http://dx.doi.org/10.2337/dc12-s101
 
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-9.
http://dx.doi.org/10.1007/BF00280883
 
14. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85:2402-10.
http://dx.doi.org/10.1210/jc.85.7.2402
 
15. Kaushik M, Mozaffarian D, Spiegelman D, et al. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am J Clin Nutr 2009; 90:613-20.
http://dx.doi.org/10.3945/ajcn.2008.27424
 
16. Heine RJ. Dietary fish oil and insulin action in humans. Ann N Y Acad Sci 1993; 683:110-21.
http://dx.doi.org/10.1111/j.1749-6632.1993.tb35698.x
 
17. Connor WE, Prince MJ, Ullmann D, et al. The hypotriglyceridemic effect of fish oil in adult-onset diabetes without adverse glucose control. Ann N Y Acad Sci 1993; 683:337-40.
http://dx.doi.org/10.1111/j.1749-6632.1993.tb35725.x
 
18. Mori TA, Bao DQ, Burke V, et al. Dietary fish as a major component of a weight-loss diet: effect on serum lipids, glucose, and insulin metabolism in overweight hypertensive subjects. Am J Clin Nutr 1999; 70:817-25.
 
19. Egert S, Fobker M, Andersen G, et al. Effects of dietary-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid on parameters of glucose metabolism in healthy volunteers. Ann Nutr Metab 2008; 53:182-7.
http://dx.doi.org/10.1159/000172980
 
20. Mahmoudabadi MM, Djalali M, Djazayery SA, et al. Effects of eicosapentaenoic acid and vitamin C on glycaemic indices, blood pressure, and serum lipids in type 2 diabetic Iranian males. J Res Med Sci 2011; 16 suppl 1:S361-7.
 
21. Griffin MD, Sanders TA, Davies IG, et al. Effects of altering the 1 ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP Study. Am J Clin Nutr 2006; 84:1290-8.
 
22. Rasic-Milutinovic Z, Perunicic G, Pljesa S, et al. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients. Ren Fail 2007; 29:321-9.
http://dx.doi.org/10.1080/08860220601184092
 
23. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83 (6 suppl):1505S-19S.
 
24. Lichtenstein AH, Schwab US. Relationship of dietary fat to glucose metabolism. Atherosclerosis 2000; 150:227-43.
http://dx.doi.org/10.1016/S0021-9150(99)00504-3
 
25. Nugent C, Prins JB, Whitehead JP, et al. Arachidonic acid stimulates glucose uptake in 3T3-L1 adipocytes by increasing GLUT1 and GLUT4 levels at the plasma membrane. Evidence for involvement of lipoxygenase metabolites and peroxisome proliferator-activated receptor gamma. J Biol Chem 2001; 276:9149-57.
http://dx.doi.org/10.1074/jbc.M009817200
 
26. Figueras M, Olivan M, Busquets S, López-Soriano FJ, Argilés JM. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity (Silver Spring) 2011; 19:362-9.
http://dx.doi.org/10.1038/oby.2010.194
 
27. Menzaghi C, Trischitta V, Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007; 56:1198-209.
http://dx.doi.org/10.2337/db06-0506
 
28. Rosenson RS. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am J Cardiol 2007; 99:96B-104B.
http://dx.doi.org/10.1016/j.amjcard.2006.11.010

Impact of bariatric surgery on the management of type 2 diabetes mellitus in Singapore

Share this Article

Singapore Med J 2013; 54(7): 382-386; http://dx.doi.org/10.11622/smedj.2013138
Impact of bariatric surgery on the management of type 2 diabetes mellitus in Singapore

Lee PC, Tham KW, Tan HC, Pasupathy S
Correspondence: Dr Kwang Wei Tham, tham.kwang.wei@sgh.com.sg

ABSTRACT
Introduction Obesity is a risk factor for type 2 diabetes mellitus (T2DM). Metabolic-bariatric surgery (MBS) results in significant weight loss with dramatic improvement in T2DM. This study analysed the effects of MBS on patients with T2DM in a tertiary centre in Singapore.
Methods Individuals with T2DM who underwent MBS in a single centre from September 2008 to May 2012, with at least 12 months of regular follow-up, were included in our study. The primary outcome measure was good glycaemic control (glycated haemoglobin [HbA1c] < 6.5%, with or without medications) 12 months after surgery. Secondary outcome measures were partial DM remission (fasting blood glucose [FBG] < 7.0 mmol/L and HbA1c < 6.5% without DM medications), complete DM remission (FBG < 5.6 mmol/L and HbA1c < 6.0% without DM medications), weight, body mass index, blood pressure, and fasting serum lipid, serum glucose and serum insulin levels.
Results Of the 19 patients who met the inclusion criteria, 14 underwent gastric bypass and 5 underwent sleeve gastrectomy. At 12 months postoperatively, 17 (89.5%) patients achieved good glycaemic control. DM remission was achieved in 14 (73.7%) patients, with 10 (52.6%) attaining complete remission.
Conclusion In Singapore, MBS is an effective treatment modality for obese patients with T2DM. Despite the small sample size and lack of matched controls, the present study suggests that MBS is effective in achieving significant weight loss and eliciting a significant and sustainable improvement in the glycaemic control of patients with T2DM, for up to 12 months. 

Keywords: bariatric surgery, diabetes mellitus, metabolic, obesity, remission
Singapore Med J 2013; 54(7): 382-386; http://dx.doi.org/10.11622/smedj.2013138

REFERENCES

1. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17:961-9.
http://dx.doi.org/10.2337/diacare.17.9.961
 
2. Ma S, Cutter J, Tan CE, Chew SK, Tai ES. Associations of diabetes mellitus and ethnicity with mortality in a multiethnic Asian population: data from the 1992 Singapore National Health Survey. Am J Epidemiol 2003; 158:543-52.
http://dx.doi.org/10.1093/aje/kwg199
 
3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12.
http://dx.doi.org/10.1136/bmj.321.7258.405
 
4. Laiteerapong N, John PM, Nathan AG, Huang ES. Public health implications of recommendations to individualize glycaemic targets in adults with diabetes. Diabetes Care 2013; 36:84-9.
http://dx.doi.org/10.2337/dc11-2344
 
5. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adultonset diabetes mellitus. Ann Surg 1995; 222:339-50.
http://dx.doi.org/10.1097/00000658-199509000-00011
 
6. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-93.
http://dx.doi.org/10.1056/NEJMoa035622
 
7. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741-52.
http://dx.doi.org/10.1056/NEJMoa066254
 
8. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307:56-65.
http://dx.doi.org/10.1001/jama.2011.1914
 
9. Dixon JB, Zimmet P, Alberti KG, Rubino F, International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med 2011; 28:628-42.
http://dx.doi.org/10.1111/j.1464-5491.2011.03306.x
 
10. Lomanto D, Lee WJ, Goel R, et al. Bariatric surgery in Asia in the last 5 years (2005-2009). Obes Surg 2012; 22:502-6.
http://dx.doi.org/10.1007/s11695-011-0547-2
 
11. Lee WJ, Chong K, Lee YC, et al. Effects of obesity surgery on type 2 diabetes mellitus Asian patients. World J Surg 2009; 33:1895-903.
http://dx.doi.org/10.1007/s00268-009-0115-2
 
12. National Health Survey. 2004 Epidemiology and Disease Control Department Ministry of Health, Singapore.
 
13. National Health Survey. 2010 Epidemiology and Disease Control Department Ministry of Health, Singapore.
 
14. Kiong KL, Ganesh R, Cheng AK, Lekshiminarayanan R, Lim SC. Early improvement in type 2 diabetes mellitus post Roux-en-Y gastric bypass in Asian patients. Singapore Med J 2010; 51:937-43.
PMid:21221498
 
15. Ministry of Health. Clinical Practice Guidelines 5/2004 Obesity. Singapore: Ministry of Health.
 
16. Lee SY, Lim CH, Pasupathy S, et al. Laparoscopic sleeve gastrectomy: a novel procedure for weight loss. Singapore Med J 2011; 52:794-800.
 
17. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007; 356:2176-83.
http://dx.doi.org/10.1056/NEJMct067019
 
18. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care 2009; 32:2133-5.
http://dx.doi.org/10.2337/dc09-9036
 
19. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-59.
http://dx.doi.org/10.1056/NEJMoa0802743
 
20. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122:248-56.e5.
 
21. Look AHEAD Research Group, Wadden TA, West DS, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) 2006; 14:737-52.
http://dx.doi.org/10.1038/oby.2006.84
 
22. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366:1577-85.
http://dx.doi.org/10.1056/NEJMoa1200111
 
23. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567-76.
http://dx.doi.org/10.1056/NEJMoa1200225
 
24. Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146:143-8.
http://dx.doi.org/10.1001/archsurg.2010.326
 
25. Rubino F, R'bibo S L, del Genio F, Mazumdar M, McGraw TE. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol 2010; 6:102-9.
http://dx.doi.org/10.1038/nrendo.2009.268

Vitamin D requirement in pregnancy to prevent deficiency in neonates: a randomised trial

Share this Article

Singapore Med J 2013; 54(5): 285-288; http://dx.doi.org/10.11622/smedj.2013110
Vitamin D requirement in pregnancy to prevent deficiency in neonates: a randomised trial

Shakiba M, Iranmanesh MR
Correspondence: Dr Mehrdad Shakiba, shakiba@ssu.ac.ir

ABSTRACT
Introduction The exact amount of vitamin D required for pregnant women to adequately supply the foetus during pregnancy is still unclear. This randomised trial attempted to determine the optimal dose of vitamin D necessary during pregnancy in order to attain a vitamin D level > 20 ng/mL in neonates.
Methods A total of 51 healthy, pregnant women in Yazd, Iran, were recruited in 2009. Of these, 34 were randomised to receive either 50,000 IU (Group A) or 100,000 IU (Group B) of vitamin D3 per month from the second trimester of pregnancy. The remaining 17 pregnant women, who formed the third group (Group C) and were found to have vitamin D deficiency, were initially treated with 200,000 IU of vitamin D3, following which the dose was adjusted to 50,000 IU per month. 25-hydroxyvitamin D (25[OH]D) in cord blood was measured by chemiluminescence immunoassay, and a serum 25(OH)D level < 20 ng/mL was defined as deficiency.
Results All the pregnant women had a vitamin D level < 30 ng/mL at the beginning of the second trimester. The neonates of 76% of women from Group A had sufficient levels of 25(OH)D. All the neonates born to women in Groups B and C had 25(OH)D > 20 ng/mL. No side effects were observed in our participants during the period of vitamin D supplementation.
Conclusion A vitamin D3dose > 50,000 IU/month is required during the second and third trimesters of pregnancy for vitamin D-deficient pregnant women in order for their neonates to achieve serum 25(OH)D levels > 20 ng/mL. Supplementation with < 50,000 IU/month is insufficient to ensure a vitamin D level > 20 ng/mL in all neonates born to vitamin D-deficient pregnant women.

Keywords: 25-hydroxyvitamin D, neonate, pregnancy, vitamin D
Singapore Med J 2013; 54(5): 285-288; http://dx.doi.org/10.11622/smedj.2013110

REFERENCES

1. Mulligan ML, Felton SK, Riek AE, Bernal-Mizrachi C. Implications of vitamin D deficiency in pregnancy and lactation. Am J Obstet Gynecol 2010; 202:429.e1-9.
 
2. Kovacs CS. Vitamin D in pregnancy and lactation: maternal, fetal, and neonatal outcomes from human and animal studies. Am J Clin Nutr 2008; 88:520S-528S.
 
3. Dror DK. Vitamin D status during pregnancy: maternal, fetal, and postnatal outcomes. Curr Opin Obstet Gynecol 2011; 23:422-6.
http://dx.doi.org/10.1097/GCO.0b013e32834cb791
 
4. Hensel KJ, Randis TM, Gelber SE, Ratner AJ. Pregnancy-specific association of vitamin D deficiency and bacterial vaginosis. Am J Obstet Gynecol 2011; 204:41.e1-9.
 
5. Bodnar LM, Catov JM, Zmuda JM, et al. Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr 2010; 140:999-1006.
http://dx.doi.org/10.3945/jn.109.119636
 
6. Leffelaar ER, Vrijkotte TG, van Eijsden M. Maternal early pregnancy vitamin D status in relation to fetal and neonatal growth: results of the multi-ethnic Amsterdam Born Children and their Development cohort. Br J Nutr 2010; 104:108-17.
http://dx.doi.org/10.1017/S000711451000022X
 
7. Mahon P, Harvey N, Crozier S, et al. Low maternal vitamin D status and fetal bone development: cohort study. J Bone Miner Res 2010; 25:14-9.
http://dx.doi.org/10.1359/jbmr.090701
 
8. Cole ZA, Gale CR, Javaid MK, et al. Maternal dietary patterns during pregnancy and childhood bone mass: a longitudinal study. J Bone Miner Res 2009; 24:663-8.
http://dx.doi.org/10.1359/jbmr.081212
 
9. Weiss ST, Litonjua AA. Childhood asthma is a fat-soluble vitamin deficiency disease. Clin Exp Allergy 2008; 38:385-7.
http://dx.doi.org/10.1111/j.1365-2222.2007.02920.x
 
10. Grant WB, Soles CM. Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. Dermatoendocrinol 2009; 1:223-8.
http://dx.doi.org/10.4161/derm.1.4.9500
 
11. Eyles DW, Feron F, Cui X, et al. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009; 34(Suppl 1):S247-57.
http://dx.doi.org/10.1016/j.psyneuen.2009.04.015
 
12. Marjamäki L, Niinistö S, Kenward MG, et al. Maternal intake of vitamin D during pregnancy and risk of advanced beta cell autoimmunity and type 1 diabetes in offspring. Diabetologia 2010; 53:1599-607.
http://dx.doi.org/10.1007/s00125-010-1734-8
 
13. Heaney RP. Defining deficiency of vitamin D [online]. Available at: http://www.cli-online.com/index.php?id=2975. Accessed November 3, 2012.
 
14. Datta S, Alfaham M, Davies DP, et al. Vitamin D deficiency in pregnant women from a non-European ethnic minority population--an interventional study. BJOG 2002; 109:905-8.
 
15. Hollis BW, Wagner CL. Vitamin D requirements during lactation: highdose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. Am J Clin Nutr 2004; 80(6 Suppl):1752S-8S.
 
16. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81.
http://dx.doi.org/10.1056/NEJMra070553
 
17. Hollis BW, Wagner CL. Vitamin D requirements and supplementation during pregnancy. Curr Opin Endocrinol Diabetes Obes 2011; 18:371-5.
 
18. van Schoor NM, Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 2011; 25:671-80.
http://dx.doi.org/10.1016/j.beem.2011.06.007
 
19. Eastern Mediterranean Regional Health System Observatory. EMRO 3: Health Status and Demographics. In: World Health Organization – Eastern Mediterranean Regional Health System Observatory [online]. Available at: http://gis.emro.who.int/HealthSystemObservatory/PDF/Iran/Health%20status.... Acessed May 15, 2013.
 
 
20. Kazemi A, Sharifi F, Jafari N, Mousavinasab N. High prevalence of vitamin D deficiency among pregnant women and their newborns in an Iranian population. J Womens Health (Larchmt) 2009; 18:835-9.
http://dx.doi.org/10.1089/jwh.2008.0954
 
21. Saadi HF, Dawodu A, Afandi BO, et al. Efficacy of daily and monthly highdose calciferol in vitamin D-deficient nulliparous and lactating women. Am J Clin Nutr 2007; 85:1565-71.
 
22.Institute of Medicine of the National Academies. Dietary Reference Intakes for Calcium and Vitamin D [online]. Available at: www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitam.... Accessed August 5, 2011.
 
23. Mallet E, Gügi B, Brunelle P, et al.Vitamin D supplementation in pregnancy: a controlled trial of two methods. Obstet Gynecol 1986; 68:300-4.
http://dx.doi.org/10.1097/00006250-198609000-00002
 
24. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77:204-10.
 
25. Sahu M, Das V, Aggarwal A, et al. Vitamin D replacement in pregnant women in rural north India: a pilot study. Eur J Clin Nutr 2009; 63:1157-9.
http://dx.doi.org/10.1038/ejcn.2009.27
 
26. Yu CK, Sykes L, Sethi M, Teoh TG, Robinson S. Vitamin D deficiency and supplementation during pregnancy. Clin Endocrinol (Oxf) 2009; 70:685-90.
http://dx.doi.org/10.1111/j.1365-2265.2008.03403.x
 
27. Canadian Paediatric Society. Vitamin D supplementation: Recommendations for Canadian mothers and infants. Paediatr Child Health 2007; 12:583-98.
 
28.Hollis B, Wagner C. Vitamin D 'may cut premature birth risk and protect new born babies' times 2009. Available at: www.timesonline.co.uk/tol/news/uk/scotland/artic le6868729.ece?token=null&offset=0&page=1. Accessed August 5, 2011.

Impact of education on ventilator-associated pneumonia in the intensive care unit

Share this Article

Singapore Med J 2013; 54(5): 281-284; http://dx.doi.org/10.11622/smedj.2013109
Impact of education on ventilator-associated pneumonia in the intensive care unit

Subramanian P, Choy KL, Gobal SV, Mansor M, Ng KH
Correspondence: Dr Pathmawathi Subramanian, pathmawathi@um.edu.my

ABSTRACT
Introduction Ventilator-associated pneumonia (VAP) is a common risk among critically ill ventilated patients. This study aimed to investigate the effects of nurse-led education on: (a) knowledge of and compliance with ventilator care bundle (VCB) practices among intensive care unit (ICU) nurses; and (b) reduction in the rates of VAP post intervention.
Methods A quasi-experimental design with pretest-posttest evaluation and observation was used to investigate nurses’ knowledge of and compliance with VCB practices, and the incidence of VAP. The study was conducted among 71 nurses, and the intervention involved structured education on VAP and its prevention using VCB in an ICU setting. Data were analysed using descriptive and inferential statistics.
Results Nurse-led education significantly increased nurses’ knowledge of (t[70] = −36.19; p < 0.001) and compliance with (t[65] = −21.41; p < 0.001) VCB practices. The incidence of VAP, which was 39 per 1,000 ventilator days during the two-month period before intervention, dropped to 15 per 1,000 ventilator days during the two-month period following intervention.
Conclusion Our findings show that nurse-led education on VAP and VCB significantly increased knowledge of and compliance with VCB practices among ICU nurses, and was associated with a reduction in the incidence of VAP among intubated and mechanically ventilated ICU patients. Inclusion of recent knowledge and evidence-based VCB guidelines for VAP prevention when educating anaesthetists, nurses, physiotherapists and other healthcare providers in the critical care setting is recommended.

Keywords: compliance, intensive care, knowledge, ventilator-associated pneumonia, ventilator care bundle
Singapore Med J 2013; 54(5): 281-284; http://dx.doi.org/10.11622/smedj.2013109

REFERENCES

1. Westwell S. Implementing a ventilator care bundle in an adult intensive care unit. Nurs Crit Care 2008; 13:203-7.
http://dx.doi.org/10.1111/j.1478-5153.2008.00279.x
 
2. Wip C, Napolitano L. Bundles to prevent ventilator-associated pneumonia: how valuable are they? Curr Opin Infect Dis 2009; 22:159-66.
http://dx.doi.org/10.1097/QCO.0b013e3283295e7b
 
3. Tolentino-DelosReyes AF, Ruppert SD, Shiao SY. Evidence-based practice: use of the ventilator bundle to prevent ventilator-associated pneumonia. Am J Crit Care 2007; 16:20-7.
 
4. Al-Tawfiq JA, Abed MS. Decreasing ventilator-associated pneumonia in adult intensive care units using the Institute for Healthcare Improvement bundle. Am J Infect Control 2010; 38:552-6.
http://dx.doi.org/10.1016/j.ajic.2010.01.008
 
5. Hunter J, Annadurai S, Rothwell M. Diagnosis, management and prevention of ventilator-associated pneumonia in the UK. Eur J Anaesthesiol 2007; 24:971-7.
http://dx.doi.org/10.1017/S0265021507001123
 
6. Efrati S, Deutsch I, Antonelli M, et al. Ventilator-associated pneumonia: current status and future recommendations. J Clin Monit Comput 2010; 24:161-8.
http://dx.doi.org/10.1007/s10877-010-9228-2
 
7. Institute for Healthcare Improvement. Implement the IHI Ventilator Bundle [online]. Available at: http://www.ihi.org/knowledge/pages/changes/implementtheventilatorbundle..... Accessed September 9, 2010.
 
8. Institute for Healthcare Improvement. Getting started kit: Preventing ventilator-associated pneumonia (100,000 lives campaign) – How-to guide.
 
9. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patient with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med [serial online] 2000; 162:505-11. Available at: http://www.atsjournals.org/. Accessed September 18, 2010.
http://dx.doi.org/10.1164/ajrccm.162.2.9909095
 
10. Pugin J. Clinical signs and scores for the diagnosis of ventilator-associated pneumonia. Minerva Anestesiol [serial online] 2002; 68:261-5. Available at: http://www.minervamedica.it/. Accessed September 16, 2010.
 
11. Apisarnthanarak A, Pinitchai U, Thongphubeth K, et al. Effectiveness of an educational program to reduce ventilator-associated pneumonia in a tertiary care center in Thailand: a 4-Year Study. Clin Infect Dis 2007; 45:704-11.
http://dx.doi.org/10.1086/520987
 
12. Hawe CS, Ellis KS, Cairns CJ, Longmate A. Reduction of ventilatorassociated pneumonia: active versus passive guideline implementation. Intensive Care Med 2009; 35:1180-6.
http://dx.doi.org/10.1007/s00134-009-1461-0
 
13. Crunden E, Boyce C, Woodman H, Bray B. An evaluation of the impact of the ventilator care bundle. Nurs Crit Care 2005; 10:242-6.
http://dx.doi.org/10.1111/j.1362-1017.2005.00134.x

Radiological findings in 31 patients with chondroblastoma in tubular and non-tubular bones

Share this Article

Singapore Med J 2013; 54(5): 275-280; http://dx.doi.org/10.11622/smedj.2013108
Radiological findings in 31 patients with chondroblastoma in tubular and non-tubular bones

Jaovisidha S, Siriapisith R, Chitrapazt N, De Zordo T, Woratanarat P, Subhadrabandhu T, Sirikulchayanonta V, Siriwongpairat P
Correspondence: Dr Suphaneewan Jaovisidha, rasjv@yahoo.com

ABSTRACT
Introduction
This study aimed to evaluate radiological findings in patients with chondroblastoma (CB) in tubular and non-tubular bones (NTBs).
Methods We retrospectively reviewed the medical records of patients with CB. Data collected included patients’ gender and age, type, size and location of bone involved, and imaging findings regarding border, lobulation, calcification, trabeculation, cortical expansion and destruction, periosteal reaction, soft tissue component and fractures. Magnetic resonance imaging and/or multidetector computed tomography were used to determine the presence of any internal cystic space or secondary aneurysmal bone cyst that may have affected the radiological appearance of CB.
Results All 31 lesions (18 tubular bones, 13 NTBs) exhibited geographic bone destruction and did not involve the adjacent joints. Univariate analysis showed that NTB lesions were found in older patients and were associated with thin trabeculation (p < 0.01) and well-defined margins (p < 0.05), whereas tubular bone lesions correlated with thick trabeculation and partially ill-defined margins. On multivariate analysis, age and type of bone involvement were significantly correlated. An increase in age by one year reduced the risk of having tubular bone involvement by about 27% when compared with NTBs (p = 0.011). Thin trabeculation was also significantly correlated with NTB lesions.
Conclusion Age was the most significant parameter, as increased age was found to reduce the risk of tubular bone involvement. Patients with NTB lesions were significantly older than those with tubular bone lesions. Based on imaging alone, thin trabeculation showed significant correlation with CB occurring in NTBs on both univariate and multivariate analyses.

Keywords: chondroblastoma, flat bone, non-tubular bone, radiograph, tubular bone
Singapore Med J 2013; 54(5): 275-280; http://dx.doi.org/10.11622/smedj.2013108

REFERENCES

1. Papaioannou G, Sebire NJ, McHugh K. Imaging of the unusual pediatric "blastomas". Cancer Imaging 2009; 9:1-11.
http://dx.doi.org/10.1102/1470-7330.2009.0001
 
2. Davila JA, Amrami KK, Sundaram M, Adkins MC, Unni KK. Chondroblastoma of the hands and feet. Skeletal Radiol 2004; 33:582-7.
http://dx.doi.org/10.1007/s00256-004-0762-1
 
3. Azouz EM. Magnetic resonance imaging of benign bone lesions: cysts and tumors. Top Magn Reson Imaging 2002; 13:219-29.
http://dx.doi.org/10.1097/00002142-200208000-00003
 
4. Garin IE, Wang EH. Chondroblastoma. J Orthop Surg (Hong Kong) 2008; 16:84-7.
 
5. Springfield DS, Capanna R, Gherlinzoni F, Picci P, Campanacci M. Chondroblastoma: A review of seventy cases. J Bone Joint Surg Am 1985; 67:748-55.
 
6. Lester EW. Neoplastic, metabolic, and inflammatory disorders of the bones and joints. In: Stocker JT, Louis PD, eds. Pediatric Pathology. Philadelphia: JB Lippincott, 1992: 1224-5.
 
7. Tachdjian MO. Bone: Benign chondroblastoma. In: Tachdjian MO, ed. Pediatric Orthopedics. 2nd ed. Philadelphia: WB Saunder, 1990: 1200-3.
 
8. Resnick D. Tumor and tumor-like lesions of bone. In: Resnick D, ed. Diagnostic of Bone and Joint Disorders. 4th Ed. Philadelphia: WB Saunder, 2002: 3850-66.
 
9. Schajowicz F, Gallardo H. Epiphysial chondroblastoma of bone. A clinicopathological study of sixty-nine cases. J Bone Joint Surg Br 1970; 52:205-26.
 
10. Aronsohn RS, Hart WR, Martel W. Metaphyseal chondroblastoma of bone. AJR Am J Roentgenol 1976; 127:686-8.
http://dx.doi.org/10.2214/ajr.127.4.686
 
11. Jarkiewicz-Kochman E, Golebiowski M, Swiatkowski J, Pacholec E, Rajewski R. Tumors of the metatarsus. Ortop Traumatol Rehabil 2007; 9:319-30.
 
12. Konishi E, Okubo T, Itoi M, et al. Chondroblastoma of trapezium with metacarpal involvement. Healio Orthopedics 2008; 31. Available at: http://www.OrthoSuperSite.com/view.asp?rID=27103. Accessed May 30, 2011.
 
13. Sessions W, Siegel HJ, Thomas J, et al. Chondroblastoma with associated aneurysmal bone cyst of the cuboid. J Foot Ankle Surg 2005; 44:64-7.
http://dx.doi.org/10.1053/j.jfas.2004.11.010
 
14. Sepah YJ, Umer M, Minhas K, Hafeez K. Chondroblastoma of the cuboid with an associated aneurismal bone cyst: a case report. J Med Case Rep 2007; 1:135. Available at: http://www.jmedicalcase reports.com/content/1/1/135. Accessed May 31, 2011.
 
 
15. Breck LW, Emmett JE. Chondroblastoma of the talus: a case report. Clin Orthop 1956; 7:132-5.
 
16.Moore TM, Roe JB, Harvey JP Jr. Chondroblastoma of the talus: a case report. J Bone Joint Surg Am 1977; 59:830-1.
 
17. Trebse R, Rotter A, Pisot V. Chondroblastoma of the patella associated with an aneurysmal bone cyst. Acta Orthop Belg 2001; 67:290-6.
 
18. Weatherall PT, Maale GE, Mendelsohn DB, et al. Chondroblastoma: classic and confusing appearance at MR imaging. Radiology 1994; 190:467-74.
 
19. Oxtoby JW, Davies AM. MRI characteristics of chondroblastoma. Clin Radiol 1996; 51:22-6.
http://dx.doi.org/10.1016/S0009-9260(96)80213-3
 
20. Jee WH, Park YK, McCauley TR, et al. Chondroblastoma: MR characteristics with pathologic correlation. J Comput Assist Tomogr 1999; 23:721-6.
http://dx.doi.org/10.1097/00004728-199909000-00016
 
21. Yamamura S, Sato K, Sugiura H, Iwata H. Inflammatory reaction in chondroblastoma. Skeletal Radiol 1996; 25:371-6.
http://dx.doi.org/10.1007/s002560050097
 
22. Brower AC, Moser RP, Kransdorf MJ. The frequency and diagnostic significance of periostitis in chondroblastoma. AJR Am J Roentgenol 1990; 154:309-14.
http://dx.doi.org/10.2214/ajr.154.2.2105021
 
23. Hayes CW, Conway WF, Sundaram M. Misleading aggressive MR imaging appearance of some benign musculoskeletal lesions. RadioGraphics 1992; 12:1119-34.
 
24. James SL, Panicek DM, Davies AM. Bone marrow oedema associated with benign and malignant bone tumours. Eur J Radiol 2008; 67:11-21.
http://dx.doi.org/10.1016/j.ejrad.2008.01.052
 
25. Keenan S, Bui-Mansfield LT. Musculoskeletal lesions with fluid-fluid level: a pictorial essay. J Comput Assist Tomogr 2006; 30:517-24.
http://dx.doi.org/10.1097/00004728-200605000-00029
 
26. McLeod RA, Beabout JW. The roentgenographic features of chondroblastoma. Am J Roentgenol Radium Ther Nucl Med 1973; 118:464-71.
http://dx.doi.org/10.2214/ajr.118.2.464
 
27. Lodwick GS, Wilson AJ, Farrell C, Virtama P, Dittrich F. Determining growth rates of focal lesions of bone from radiographs. Radiology 1980; 134:577-83.
 
28. Dorfman HD, Czerniak B. General consideration. In: Dorfman HD, Czerniak B, eds. Bone Tumors. St Louis: Mosby, 1998: 1-7.
 
29. Bloem JL, Mulder JD. Chondrobalstoma: A clinical and radiological study of 104 cases. Skeletal Radiol 1985; 14:1-9.
http://dx.doi.org/10.1007/BF00361187
 
30. Ramappa AJ, Lee FY, Tang P, et al. Chondroblastoma of bone. J Bone Joint Surg Am 2000; 82:1140-5.
 
31. Schajowicz F. Chondroblastoma. In: Schajowicz F ed. Tumors and Tumorlike Lesions of Bone: Pathology, Radiology and Treatment. Berlin: Springer Verlag, 1994: 173-89.
http://dx.doi.org/10.1007/978-3-642-49954-8
 
32. D'Ambrosia R, Ferguson AB Jr. The formation of osteochondroma by epiphyseal cartilage transplantation. Clin Orthop Relat Res 1968; 61:103-15.
 
33. Larocca H. Embryology of the neuromusculoskeletal apparatus. In: Lowell WW, Winter RB, eds. Pediatric Orthopaedic. Philadelphia: JB Lippincott, 1986: 1-39.
 
34. Sarrafian SK. Anatomy of the foot and ankle. Philadelphia: JB Lippincott; 1983: 47-54.
 
35. Kleiger B. Injuries of the talus and its joints. Clin Orthop Relat Res 1976; 121:243-62.
 
36. Dorfman HD, Czerniak B. Benign cartilage lesions. In: Dorfman HD, Czerniak B, eds. Bone Tumors. St Louis: Mosby, 1998: 296-321.

Duplex ultrasonography arteriography as first-line investigation for peripheral vascular disease

Share this Article

Singapore Med J 2013; 54(5): 271-274; http://dx.doi.org/10.11622/smedj.2013107
Duplex ultrasonography arteriography as first-line investigation for peripheral vascular disease

Wong TH, Tay KH, Sebastian MG, Tan SG
Correspondence: Dr Ting Hway Wong, wong.th@doctors.org.uk

ABSTRACT
Introduction
The gold standard for evaluation of the lower extremity arterial tree is catheter angiography. Duplex arterial-occlusive imaging or duplex ultrasonography arteriography, a noninvasive technique, is used as the first-line investigation in patients with peripheral vascular disease at our centre. Based on the results of duplex imaging, patients who require angiographic intervention then proceed with simultaneous catheter arteriography and intervention. This study aimed to compare the results of duplex imaging alone as the first-line investigation against the eventual results of catheter angiography, and to assess the impact of the former on patients’ clinical outcomes.
Methods All cases involving patients who underwent duplex imaging followed by angiographic intervention, from May 2008 to February 2009, were discussed at weekly interdisciplinary meetings. Only patients who underwent lower limb imaging were included in the study. Those who were involved in grafts and stent surveillance studies, as well as those with incomplete duplex images were excluded.
Results During the study period, 113 duplex imaging studies of the lower limb followed by percutaneous transluminal angioplasty were performed at our hospital for peripheral vascular disease. The iliac artery was visualised in 40 images, but could not be visualised in 73 images. There was a potential change in management in three cases due to radiological differences between the duplex images and angiography films.
Conclusion In our series, duplex imaging was found to be accurate enough to guide initial clinical management of patients with peripheral vascular disease. This modality is the preferred first-line investigation for such patients at our centre.

Keywords: arterial-occlusive imaging, duplex ultrasonography, peripheral vascular disease
Singapore Med J 2013; 54(5): 271-274; http://dx.doi.org/10.11622/smedj.2013107

REFERENCES

1. Ascher E, Hingorani A, Markevich N, Schutzer R, Kallakuri S. Acute lower limb ischemia: the value of duplex ultrasound arterial mapping (DUAM) as the sole preoperative imaging technique. Ann Vasc Surg 2003; 17:284-9.
http://dx.doi.org/10.1007/s10016-001-0263-9
 
2. Ascher E, Mazzariol F, Hingorani A, Salles-Cunha S, Gade P. The use of duplex ultrasound arterial mapping as an alternative to conventional arteriography for primary and secondary infrapopliteal bypasses. Am J Surg 1999; 178:162-5.
http://dx.doi.org/10.1016/S0002-9610(99)00151-8
 
3. Collins R, Burch J, Cranny G, et al. Duplex ultrasonography, magnetic resonance angiography and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review. BMJ 2007; 334:1257-61.
http://dx.doi.org/10.1136/bmj.39217.473275.55
 
4. Ouwendijk R, de Vries M, Stijnen T, et al. Multicenter randomized controlled trial of the costs and effects of noninvasive diagnostic imaging in patients with peripheral arterial disease: the DIPAD trial. AJR Am J Roentgenol 2008; 190:1349-57.
http://dx.doi.org/10.2214/AJR.07.3359
 
5. Hingorani A, Ascher E, Marks N. Preprocedural imaging: new options to reduce need for contrast angiography. Semin Vasc Surg 2007; 20:15-28.
http://dx.doi.org/10.1053/j.semvascsurg.2007.02.005
 
6. Favaretto E, Pili C, Amato A, et al. Analysis of agreement between Duplex ultrasound scanning and arteriography in patients with lower limb artery disease. J Cardiovasc Med (Hagerstown) 2007; 8:337-41.
http://dx.doi.org/10.2459/01.JCM.0000268124.51543.b2
 
7. Hingorani AP, Ascher E, Marks N, et al. Limitations of and lessons learned from clinical experience of 1,020 duplex arteriography. Vascular 2008; 16:147-53.
http://dx.doi.org/10.2310/6670.2008.00014
 
8. Met R, Bipat S, Legemate DA, Reekers J A, Koelemay, MJ. Diagnostic Performance of Computed Tomography Angiography in Peripheral Arterial Disease: A Systematic Review and Meta-analysis. JAMA 2009; 301:415-24.
http://dx.doi.org/10.1001/jama.301.4.415
 
9. Bradbury AW, Adam DJ. Diagnosis of peripheral arterial disease of the lower limb. BMJ 2007; 334:1229-30.
http://dx.doi.org/10.1136/bmj.39244.344664.80

Excretory urography and renal scintigraphy for chronic obstructed kidney: does nonopacity mean nonsalvageability?

Share this Article

Singapore Med J 2013; 54(5): 267-270; http://dx.doi.org/10.11622/smedj.2013106
Excretory urography and renal scintigraphy for chronic obstructed kidney: does nonopacity mean nonsalvageability?

Klaipetch A, Namwongprom S, Ekmahachai M, Lojanapiwat B
Correspondence: Dr Alisa Klaipetch, aklaipet@med.cmu.ac.th

ABSTRACT
Introduction
This study aimed to ascertain whether nonopacified kidney on excretory urography (also known as intravenous urography [IVU]) indicates nonsalvageability.
Methods We retrospectively reviewed 45 adult patients with chronic unilateral urinary tract obstruction, in whom IVU revealed nonopacified kidney on one side but normal excretion on the contralateral side. Affected kidneys with split glomerular filtration rate (GFR) < 10 mL/min/1.73 m2 on 99mTc-diethylenetriaminepentaacetic acid diuretic renal scintigraphy were considered nonsalvageable. Non-function was defined based on cutoff points (< 15% and < 20%) to determine the sensitivity and specificity of differential renal function. Differences in IVU and renal scintigraphy findings, with respect to the duration of delayed filming on IVU, were analysed for significance.
Results The results of IVU and renal scintigraphy findings for 34 (75.6%) nonopacified kidneys matched, representing nonsalvageable kidneys. Sensitivity and specificity of differential renal function were 76% and 100%, respectively, when the cutoff point for non-function was set at < 15%. Sensitivity and specificity were 97% and 82%, respectively, when the cutoff point was < 20%. There was no significant difference between renal scintigraphy findings and IVU with 2-hour and > 2-hour delayed films (p = 0.96).
Conclusion Although most nonopacified kidneys on IVU were nonsalvageable, a quarter of them were found to be salvageable on renal scintigraphy. Besides split GFR, differential function at cutoff point < 15% could be used to determine non-function of a chronic obstructed kidney when the contralateral kidney is normal. Delayed filming beyond two hours appears unnecessary in ensuring non-excretion on IVU.

Keywords: chronic obstruction, differential renal function, excretory urography, nonsalvageable, renal scintigraphy
Singapore Med J 2013; 54(5): 267-270; http://dx.doi.org/10.11622/smedj.2013106

REFERENCES

1. Kinn AC. Ureteropelvic junction obstruction: long-term followup of adults with and without surgical treatment. J Urol 2000; 164:652-6.
http://dx.doi.org/10.1016/S0022-5347(05)67274-6
 
2. Kubba AK, Hollins GW, Deane RF. Nephrectomy: changing indications, 1960-1990. Br J Urol 1994; 74:274-8.
http://dx.doi.org/10.1111/j.1464-410X.1994.tb16609.x
 
3. Thomas HS. Hsu SS, Stephen YN. Management of Upper Urinary Tract Obstruction. In: Campbell MF, Walsh PC, Wein AJ, Kavoussi LR, eds. Campbell-Walsh Urology. 9th ed. Philadelphia: Saunders Elsevier, 2007: 1228-32.
 
4. Novick AC, Stream SB. Surgery of kidney. In: Campbell MF, Walsh PC, eds. Campbell's Urology. 6th ed. Philadelphia: Saunders, 1992: 2428-48.
 
5. Davidson AJ, Hartman DS, Choyke PL, et al. Obstructive uropathy. In: Davidson AJ, ed. Davidson's Radiology of the Kidney and Genitourinary Tract. 3rd ed. Philadelphia: Saunders, 1999: 201-2.
 
6. Shokeir AA, Provoost AP, Nijman RJ. Recoverability of renal function after relief of chronic partial upper urinary tract obstruction. BJU Int 1999; 83:11-7.
http://dx.doi.org/10.1046/j.1464-410x.1999.00889.x
 
7. Bassiouny IE. Salvage pyeloplasty in nonvisualizing hydronephrotic kidney secondary to ureteropelvic junction obstruction. J Urol 1992; 148:685-7.
 
8. Carlsen O. The gamma camera as an absolute measurement device: determination of glomerular filtration rate in 99mTc-DTPA renography using a dual head gamma camera. Nucl Med Commun 2004; 25:1021-9.
http://dx.doi.org/10.1097/00006231-200410000-00006
 
9. Fotopoulos A, Bokharhli JA, Tsiouris S, et al. [Comparison of six radionuclidic and non-radionuclidic methods for the assessment of glomerular filtration rate in patients with chronic renal failure.] Hell J Nucl Med 2006; 9:133-40. Greek.
 
10. Khalaf IM, Shokeir AA, El-Gyoushi FI, Amr HS, Amin MM. Recoverability of renal function after treatment of adult patients with unilateral obstructive uropathy and normal contralateral kidney: a prospective study. Urology 2004; 64:664-8.
http://dx.doi.org/10.1016/j.urology.2004.05.018
 
11. Thomson A, Gough DC. The use of renal scintigraphy in assessing the potential for recovery in the obstructed renal tract in children. BJU Int 2001; 87:853-6.
http://dx.doi.org/10.1046/j.1464-410x.2001.02213.x
 
12. Sreenevasan G. Bilateral renal calculi. Ann R Coll Surg Engl 1974; 55:3-12.
 
13. Maenhout A, Ham H, Ismaili K, et al . Supranormal renal function in the unilateral hydronephrosis: does it represent true hyperfunction? Pediatr Nephrol 2005; 20:1762-5.
http://dx.doi.org/10.1007/s00467-005-2049-8
 
14. Piepsz A, Ismaili K, Hall M, et al. How to interpret a deterioration of split function? Eur Urol 2005; 47:686-90.
http://dx.doi.org/10.1016/j.eururo.2004.10.028
 
15. Tanagho EA, McAninch JW. Radiology of the urinary tract. In: Smith DR, Tanagho EA, McAninch JW, eds. Smith's General Urology. 16th ed. New York: McGraw-Hill, 2004: 65.
 
16. Dunnick NR, Sandler CM, Newhouse JH, Amis ES. Textbook of Uroradiology. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2007: 44.
 
17. Kelalis PP, King LR, Belman AB. Clinical Pediatric Urology. 3rd ed. Philadelphia: Saunders, 1992: 701-3.

Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study

Share this Article

Singapore Med J2013; 54(5): 263-266; http://dx.doi.org/10.11622/smedj.2013105
Clinical efficacy of sevelamer hydrochloride in patients with end-stage renal disease: a retrospective study

Alam S, Hussain A, Daiwajna R, Tan J
Correspondence: Dr Sartaj Alam, drsartajalam@hotmail.com

ABSTRACT
Introduction Sevelamer hydrochloride (Renagel) is frequently used as a second-line phosphate binder in patients on renal replacement therapy. Many studies have shown that sevelamer can improve vascular calcification, serum uric acid and low-density lipoprotein (LDL) cholesterol levels. The main objectives of this study were to assess the efficacy of sevelamer against calcium-based phosphate binders, as well as its tolerability and side-effect profile.
Methods This was a retrospective study that included all patients on renal replacement therapy (between 2008 and 2011) who had previously received calcium-based binders for ≥ 6 months and were subsequently switched to sevelamer. Data collected from the patients’ medical records included demographics, as well as renal parameters three months prior to sevelamer treatment, and at three and six months post treatment. The study excluded patients on multiple, concomitant phosphate binders or with functioning renal transplants, and those who were noncompliant or had inadequate follow-up blood investigations.
Results A total of 39 patients were included in the study. No major side effects were reported by any of the patients. There were improvements in calcium, phosphate, uric acid and LDL cholesterol levels at three and six months post-sevelamer treatment.
Conclusion We found sevelamer to be superior to calcium-based phosphate binders in reducing serum calcium, phosphate, uric acid and LDL cholesterol levels in our patient population with advanced renal bone disease. Sevelamer also appears to be well tolerated with no significant side effects.

Keywords: calcium-based binders, dialysis, phosphate binders, renagel, sevelamer
Singapore Med J2013; 54(5): 263-266; http://dx.doi.org/10.11622/smedj.2013105

REFERENCES

1. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 2006; 70:351-7.
http://dx.doi.org/10.1038/sj.ki.5001542
 
2. Block GA, Port FK. Re-evaluation of risk associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000; 35:1226-37.
http://dx.doi.org/10.1016/S0272-6386(00)70064-3
 
3. Kuhlmann MK. Management of hyperphosphatemia. Hemodial Int 2006; 10:338-45.
http://dx.doi.org/10.1111/j.1542-4758.2006.00126.x
PMid:17014508
 
4. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17:340-5.
http://dx.doi.org/10.1093/ndt/17.2.340
 
5. Mudge DW Johnson DW, Hawley CM, et al. Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice? BMC Nephrol 2011; 12:20.
http://dx.doi.org/10.1186/1471-2369-12-20
 
6. Hutchinson AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011; 7:578-89.
http://dx.doi.org/10.1038/nrneph.2011.112
 
7. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-52.
http://dx.doi.org/10.1046/j.1523-1755.2002.00434.x
 
8. Qunibi W Moustafa M, Muenz LR, et al. A 1 year randomised trial of calcium acetate versus sevelamer on progression of coronary artery calcification in haemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51:952-65.
http://dx.doi.org/10.1053/j.ajkd.2008.02.298
 
9. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-24.
http://dx.doi.org/10.1111/j.1523-1755.2005.00600.x
 
10. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71:438-41.
http://dx.doi.org/10.1038/sj.ki.5002059
PMid:17200680
 
11. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72:1255-61.
http://dx.doi.org/10.1038/sj.ki.5002518
 
12. St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51:445-54.
http://dx.doi.org/10.1053/j.ajkd.2007.12.002
PMid:18295060
 
13. Garg JP, Chasan-Taber S, Blair A, et al. Effects of sevelamer and calciumbased phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis Rheum 2005; 52:290-5.
http://dx.doi.org/10.1002/art.20781
 
14. Shantouf R, Budoff MJ, Ahmadi N, et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 2008; 28:275-9.
http://dx.doi.org/10.1159/000111061
 
15. Ferramosca E, Burke S, Chasan-Taber S, et al.: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149:820-5.
http://dx.doi.org/10.1016/j.ahj.2004.07.023
 
16. Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med 2009; 48:415-20.
http://dx.doi.org/10.2169/internalmedicine.48.1817
 
17. Shaheen FA, Akeel NM, Badawi LS, Souqiyyeh MZ. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25:785-91.
 
18. Lieu YL, Lin HH, Yu CC, et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail 2006; 28:701-7.
http://dx.doi.org/10.1080/08860220600925388
 
19. Chow KM, Szeto CC, Kwan BC, Leung CB, Li PK. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources. J Nephrol 2007; 20:674-82.
 
20. Lo WK, Cheng SW, Ng SY, et al. Efficacy and side effects of sevelamer hydrochloride as sole phosphate binder in peritoneal dialysis patients with severe hyperphosphatemia. Perit Dial Int 2008; 28:93-5.
 
21. Gulati A, Sridhar V, Bose T, Hari P, Bagga A. Short-term efficacy of sevelamer versus calcium acetate in patients with chronic kidney disease stage 3-4. Int Urol Nephrol 2010; 42:1055-62.
http://dx.doi.org/10.1007/s11255-009-9688-9
 
22. Lin YF, Chen YM, Hung KY, et al. Benefits of sevelamer on markers of bone turnover in Taiwanese hemodialysis patients. J Formos Med Assoc 2010; 109:663-72.
http://dx.doi.org/10.1016/S0929-6646(10)60107-6

Occurrence of a lymphocele following renal transplantation

Share this Article

Singapore Med J 2013; 54(5): 259-262; http://dx.doi.org/10.11622/smedj.2013104
Occurrence of a lymphocele following renal transplantation

Sim A, Ng LG, Cheng C
Correspondence:  Dr Allen Sim, allen_sim@hotmail.com

ABSTRACT
Introduction The incidence of lymphoceles – lymphatic collections around a transplanted kidney – can be as high as 20%. We aimed to review the presentation, treatment and outcome of patients with lymphoceles.
Methods We reviewed a prospective database of 154 patients who underwent renal transplantation at our hospital from January 2005 to November 2008.
Results The mean age of the patients in our cohort was 46 (range 34–58) years. The incidence of lymphoceles in our series was 5.8% (n = 9). The median onset was 19 (range 6–28) days post-transplantation, while the median size of the lymphoceles was 5 (range 1.5–8) cm. Lymphoceles were most commonly found at the lower pole of the transplanted kidney. Eight patients with lymphoceles had received cadaveric transplants. While a majority of these patients did not have hydronephrosis on presentation, four had markedly elevated creatinine. Of the nine patients with lymphoceles, six were on macrolides (tacrolimus, sirolimus or everolimus), two were successfully managed conservatively, three were managed percutaneously and four required surgical drainage via either laparoscopic marsupialisation (n = 1) or open drainage (n = 3). There was no graft loss.
Conclusion It remains unknown whether the choice of immunosuppressants increases the risk of lymphocele formation. Intervention is necessary in the case of impaired drainage of the pelvicalyceal system in these patients. Minimally invasive intervention, while effective in treating lymphoceles, does not provide definitive treatment. Surgical intervention should be considered early for the treatment of post-transplantation patients with lymphoceles, so as to shorten hospital stay and prevent further complications.

Keywords: lymphocele, renal transplant
Singapore Med J 2013; 54(5): 259-262; http://dx.doi.org/10.11622/smedj.2013104

REFERENCES

1. Braun WE, Banowsky LH, Straffon RA, et al. Lymphocele associated with renal transplantation: Report of 15 cases and review of the literature. Am J Med 1974; 57:714-29.
http://dx.doi.org/10.1016/0002-9343(74)90845-6
 
2. Hsu TH, Gill IS, Grune MT, et al. Laparoscopic lymphocelectomy: a multiinstitutional analysis. J Urol 2000; 163:1096-8.
http://dx.doi.org/10.1016/S0022-5347(05)67700-2
 
3. Fuller TF, Kang SM, Hirose R, et al. Laparoscopic treatment of symptomatic lymphocele after renal transplantation: laparoscopic versus open drainage. J Urol 2003; 169:2022-5.
http://dx.doi.org/10.1097/01.ju.0000063800.44792.61
 
4. Zuckerman DA, Yeager TD. Percutaeneous ethanol sclerotherapy of postoperative lymphoceles. AJR Am J Roentgenol 1997; 169:433-7.
http://dx.doi.org/10.2214/ajr.169.2.9242748
 
5. Hamza A, Fischer K, Koch E, et al. Diagnostic and therapy of lymphoceles after kidney transplantation. Transplant Proc 2006; 38:701-6.
http://dx.doi.org/10.1016/j.transproceed.2006.01.065
 
6. Tasar M, Gulec B, Saglam M, et al. Posttransplant symptomatic lymphocele treatment with percutaneous drainage and ethanol sclerosis: long term follow up. Clin Imaging 2005; 29:109-16.
http://dx.doi.org/10.1016/j.clinimag.2004.04.028
 
7. Atray NK, Moore F, Zaman F, et al. Post transplant lymphocele: a single centre experience. Clin Transplant 2004; 18 suppl 12:46-9.
http://dx.doi.org/10.1111/j.1399-0012.2004.00217.x
 
8. Kim JK, Jeong YY, Kim YH, et al. Postoperative pelvic lymphocele: treatment with simple percutaneous catheter drainage. Radiology 1999; 212:390-4.
 
9. Bischof G, Rockenschaub S, Berlakovich G, et al. Management of lymphoceles after kidney transplantation. Transpl Int 1998; 11:277-80 .
http://dx.doi.org/10.1111/j.1432-2277.1998.tb00970.x
 
10. Manfro RC, Comerlato L, Berdichevski RH, et al. Nephrotoxic acute renal failure in a renal transplant patient with recurrent lymphocele treated with povidone-iodine irrigation. Am J Kidney Dis 2002; 40:655-7.
http://dx.doi.org/10.1053/ajkd.2002.34930
 
11. Adani GL, Baccarani U, Bresadola V, et al. Graft loss due to percutaneous sclerotherapy of a lymphocele using acetic acid after renal transplantation. Cardiovasc Intervent Radiol 2005; 28:836-8.
http://dx.doi.org/10.1007/s00270-005-0002-7
 
12. Krol R, Kolonko A, Chudek J, et al. Did volume of lymphocele after kidney transplantation determine the choice of treatment modality? Transplant Proc 2007; 39:2740-3.
http://dx.doi.org/10.1016/j.transproceed.2007.08.039
 
13. Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A 1994; 91:12574-8.
http://dx.doi.org/10.1073/pnas.91.26.12574
 
14. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356:194-202.
http://dx.doi.org/10.1016/S0140-6736(00)02480-6
 
15. Srivastava A, Muruganandham K, Vinodh PB, et al. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors. Int Urol Nephrol 2010; 42:279-84.
http://dx.doi.org/10.1007/s11255-009-9601-6

The practice of nondisclosure of advanced cancer diagnosis in Singapore: a continuing challenge

Share this Article

Singapore Med J 2013; 54(5): 255-258; http://dx.doi.org/10.11622/smedj.2013103
The practice of nondisclosure of advanced cancer diagnosis in Singapore: a continuing challenge

Kao YH, Goh CR
Correspondence: Dr Yung Hsiang Kao, yung.h.kao@gmail.com

ABSTRACT
Introduction The traditional family-centred approach to cancer management in Singapore often leads to nondisclosure of diagnosis to patients with advanced cancer. This study aimed to determine the rate of nondisclosure to such patients in Singapore, and compare it against the rate of nondisclosure to patients’ families and that of a study conducted in 1992.
Methods Consecutive patients (n = 100) with advanced cancer who were referred to a palliative home care service in 2004 were studied retrospectively. Comparison between the 1992 and present study groups was performed using chi-square and Fisher’s exact tests. Multivariate logistic regression was applied to patient age, Eastern Cooperative Oncology Group (ECOG) performance status, gender and ethnicity to identify factors associated with nondisclosure.
Results The overall nondisclosure rate among patients with advanced cancer was 23% (23/100), compared to only 2% (2/99) among their families (p < 0.001). The nondisclosure rates among ECOG 0–2 and ECOG 3–4 patients were 11% (7/62) and 42% (16/38), respectively (p < 0.001). There was no significant improvement in the nondisclosure rate among ECOG 3–4 patients when compared to the 1992 study (p = 0.94). It was more likely for nondisclosure to occur among patients aged ≥ 70 years (p < 0.001; odds ratio [OR] 14.77, 95% confidence interval [CI] 3.68–59.26) and those with poor ECOG performance status (p = 0.019; OR 4.0, 95% CI 1.26–12.73). There was no significant association between nondisclosure and gender or ethnicity (p > 0.05).
Conclusion Disclosure of diagnosis to patients with advanced cancer remains a challenge in Singapore. The relationship between nondisclosure and advanced age, as well as nondisclosure and poor ECOG performance status, needs to be clarified with further studies.

Keywords: cancer, diagnosis disclosure, family-centred, palliative, Singapore
Singapore Med J 2013; 54(5): 255-258; http://dx.doi.org/10.11622/smedj.2013103

REFERENCES

1. Lee A, Wu HY. Diagnosis disclosure in cancer patients—when the family says "no!". Singapore Med J 2002; 43:533-8.
 
2. Back MF, Huak CY. Family centred decision making and non-disclosure of diagnosis in a South East Asian oncology practice. Psychooncology 2005; 14:1052-9.
http://dx.doi.org/10.1002/pon.918
 
3. Tay WK, Shaw RJ, Goh CR. A survey of symptoms in hospice patients in Singapore. Ann Acad Med Singapore 1994; 23:191-6.
PMid:8080223
 
4. Yun YH, Kwon YC, Lee MK, et al. Experiences and attitudes of patients with terminal cancer and their family caregivers toward the disclosure of terminal illness. J Clin Oncol 2010; 28:1950-7.
http://dx.doi.org/10.1200/JCO.2009.22.9658
PMid:20212258
 
5. Jiang Y, Liu C, Li JY, et al. Different attitudes of Chinese patients and their families toward truth telling of different stages of cancer. Psychooncology 2007; 16:928-36.
http://dx.doi.org/10.1002/pon.1156
 
6. Yun YH, Lee CG, Kim SY, et al. The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol 2004; 22:307-14.
http://dx.doi.org/10.1200/JCO.2004.07.053
 
7. Wang SY, Chen CH, Chen YS, Huang HL. The attitude toward truth telling of cancer in Taiwan. J Psychosom Res 2004; 57:53-8.
http://dx.doi.org/10.1016/S0022-3999(03)00566-X
 
8. Miyata H, Takahashi M, Saito T, et al. Disclosure preferences regarding cancer diagnosis and prognosis: to tell or not to tell? J Med Ethics 2005; 31:447-51.
http://dx.doi.org/10.1136/jme.2003.007302
PMid:16076967 PMCid:PMC1734201
 
9. Chiu LQ, Lee WS, Gao F, et al. Cancer patients' preferences for communication of unfavourable news: an Asian perspective. Support Care Cancer 2006; 14:818-24.
http://dx.doi.org/10.1007/s00520-005-0911-7
 
10. Seow A, Koh WP, Chia KS, et al. Trends in cancer incidence in Singapore 1968-2002. Singapore Cancer Registry Report No. 6. Singapore: National Registry of Diseases Office, 2004.
 
11. Chan D, Goh LG. The doctor-patient relationship: a survey of attitudes and practices of doctors in Singapore. Bioethics 2000; 14:58-76.
http://dx.doi.org/10.1111/1467-8519.00180
 
12. Lin CC, Tsay HF. Relationships among perceived diagnostic disclosure, health locus of control, and levels of hope in Taiwanese cancer patients. Psychooncology 2005; 14:376-85.
http://dx.doi.org/10.1002/pon.854
PMid:15386760
 
13. Phungrassami T, Sriplung H, Roka A, et al. Disclosure of a cancer diagnosis in Thai patients treated with radiotherapy. Soc Sci Med 2003; 57:1675-82.
http://dx.doi.org/10.1016/S0277-9536(02)00552-X
 
14. Horikawa N, Yamazaki T, Sagawa M, Nagata T. Changes in disclosure of information to cancer patients in a general hospital in Japan. Gen Hosp Psychiatry 2000; 22:37-42.
http://dx.doi.org/10.1016/S0163-8343(99)00042-0
 
15. Miyata H, Tachimori H, Takahashi M, Saito T, Kai I. Disclosure of cancer diagnosis and prognosis: a survey of the general public's attitudes toward doctors and family holding discretionary powers. BMC Med Ethics 2004; 5:E7.
http://dx.doi.org/10.1186/1472-6939-5-7
PMid:15571636 PMCid:PMC538752
 
16. Fujimori M, Uchitomi Y. Preferences of cancer patients regarding communication of bad news: a systematic literature review. Jpn J Clin Oncol 2009; 39:201-16.
http://dx.doi.org/10.1093/jjco/hyn159
 
17. Tan TK, Teo FC, Wong K, Lim HL. Cancer: to tell or not to tell? Singapore Med J 1993; 34:202-3.
PMid:8266172
 
18. Lin CC. Disclosure of the cancer diagnosis as it relates to the quality of pain management among patients with cancer pain in Taiwan. J Pain Symptom Manage 1999; 18:331-7.
http://dx.doi.org/10.1016/S0885-3924(99)00091-3
 
19. Horikawa N, Yamazaki T, Sagawa M, Nagata T. The disclosure of information to cancer patients and its relationship to their mental state in a consultation-liaison psychiatry setting in Japan. Gen Hosp Psychiatry 1999; 21:368-73.
http://dx.doi.org/10.1016/S0163-8343(99)00026-2
 
20. Buckman R. Talking to patients about cancer. BMJ 1996; 313:699-700.
http://dx.doi.org/10.1136/bmj.313.7059.699
 
21. Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol 1995; 13:2449-56.
 
22. Ngo-Metzger Q, August KJ, Srinivasan M, Liao S, Meyskens FL Jr. End-of-Life care: guidelines for patient-centered communication. Am Fam Physician 2008; 77:167-74.
 
23. Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. Med J Aust 2007; 186(12 Suppl):S77, S79, S83-108.
 
24. Economist Intelligence Unit. The quality of death. Ranking end-of-life care across the world. London: Economist Intelligence Unit, 2010.